Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multip... Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Mehr anzeigen
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation...
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.5537 | 19.4622144112 | 2.845 | 3.4095 | 2.5 | 710459 | 2.68711077 | CS |
| 4 | -1.0513 | -23.6247191011 | 4.45 | 4.55 | 2.5 | 582290 | 3.34599527 | CS |
| 12 | -1.6313 | -32.4314115308 | 5.03 | 6.53 | 2.5 | 430194 | 4.32056375 | CS |
| 26 | -7.5913 | -69.0746132848 | 10.99 | 19.688 | 2.5 | 612089 | 8.39783371 | CS |
| 52 | -10.2973 | -75.1847254673 | 13.696 | 19.688 | 2.5 | 4676485 | 13.1423084 | CS |
| 156 | -67.9013 | -95.2332398317 | 71.3 | 72.4 | 2.5 | 4783496 | 31.94244585 | CS |
| 260 | -78.8013 | -95.8653284672 | 82.2 | 135.8 | 2.5 | 4108961 | 47.2244178 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
